Skip to main content

Table 1 Baseline characteristics of participating families and allergy related disease in the children at 2 years

From: Atopic dermatitis prevention in children following maternal probiotic supplementation does not appear to be mediated by breast milk TSLP or TGF-β

Characteristics Probiotic Placebo
n   n  
Age, mother, yrs mean (SD) 129 30.5 (3.9) 130 30.3 (4.1)
Sex (male), child, n (%) 129 67 (51.9) 130 53 (40.8)
Siblings, n (%) 129 60 (46.5) 130 54 (41.5)
Atopy in family, n (%) 129 91 (70.5) 130 96 (73.9)
Maternal atopy, n (%) 129 58 (45.0) 129 68 (52.7)
Maternal smokinga, n (%) 129 9 (7.0) 130 11 (8.5)
Compliantb, n(%) 125 113 (90.4) 128 115 (89.8)
Allergy related disease at 2 years n n (%) n n (%) p-valuec
Atopic dermatitis, n (%) 129 29 (22.5) 130 45 (34.6) 0.031
Asthma, n (%) 129 7 (5.4) 130 12 (9.2) 0.240
Allergic rhinoconjunctivits, n (%) 125 1 (0.8) 129 0 (0.0) 0.492
Sensitisationd, n (%) 122 19 (15.6) 124 15 (12.1) 0.429
  1. aMaternal smoking reported during pregnancy, 6 weeks or 12 months postpartum; b Compliance with the study protocol was defined by consumption of the study milk on at least 50 % of days from 36 weeks gestation to 12 postpartum, no consumption of other products with probiotics and at least partial breastfeeding until 3 months postpartum; c p-value calculated using χ2-test, except for allergic rhinoconjunctivits where a Fisher’s exact p value is reported; d Allergic sensitisation defined as positive skin prick test (wheal ≥ 3 mm) and or positive sIgE (≥ 0.35 kUL−1)